Endocrine Abstracts

Background: Immune checkpoint inhibitors (ICIs) have modified the outcome of several advanced malignancies. Thyroid dysfunctions (DYSTHYR) are the most common endocrine immune-related adverse events (IRAEs) during treatment with the programmed cell death protein-1 (PD-1) and its ligand (PD-L1) inhibitors. Data regarding predictive biomarkers enabling stratification of DYSTHYR risk are still limited.Patients and methods: We retrospectively analyzed patien...

Background: Immune checkpoint inhibitors (ICIs) showed impressive results in several malignancies; however, a large spectrum of immune-related adverse events (IRAEs) may occur, including thyroid dysfunction (DYSTHYR). IRAEs seem to be associated with better cancer outcome; limited data suggested that thyroid toxicity could be a predictor of response to ICIs.Patients and methods: We retrospectively evaluated all patients who started treatment with the pro...

Parathyroid carcinoma (PC) is a rare neoplasia responsible for about 1% of primary hyperparathyroidism (PHPT). Differently from patients with its benign counterpart, the phenotype of these patients is characterized by severe PHPT and hypercalcemia. The aim of this study was to describe a series of PC casesrecorded in the regional cancer network of Piedmont and Valle d’Aosta, Italy (Rete Oncologica del Piemonte e della Valle d’Aosta) from 2007 to 2017, including 25 ...